Live Breaking News & Updates on Seattle Based Juno

Stay updated with breaking news from Seattle based juno. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public

Eliem Therapeutics files for IPO as another Seattle-area biotech firm set to go public
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.

United States , Andrew Levin , Bob Azelby , Lyell Immunopharma , Sujal Patel , Erinm Lavelle , Valerie Morisset , Exchange Commission , Convergence Pharmaceuticals , Capital Group , Isilon Systems , Eliem Photo , Juno Therapeutics , Alder Biopharmaceuticals , Seattle Based Juno , Sana Biotechnology , Impel Neuropharma , South San Francisco , Seattle Based Nautilus Biotechnology , Athenen Therapeutics , Intermediate Capital Group , Access Biotechnology , Samlyn Capital , Acorn Bioventures , ஒன்றுபட்டது மாநிலங்களில் , ஆண்ட்ரூ லெவின் ,

Seattle neurology startup Eliem Therapeutics raises $60M, two months after landing $80M

Seattle neurology startup Eliem Therapeutics raises $60M, two months after landing $80M
May 24, 2021 at 11:03 am
Bob Azelby. (Eliem Photo)
New funding: Eliem Therapeutics raised $60 million to further development of its therapies for pain and depression. The fresh funding comes just two months after Eliem raised a $80 million round.
The pipeline: Founded in 2019, the company has two lead drug candidates in development: ETX-810 for chronic pain and ETX-155 for major depressive disorder, hormone-related mood disorders, and focal onset seizures. Both are in Phase 2a clinical trials.
ETX-810 is described as an investigational non-opioid that uses the palmitoylethanolamide (PEA) pathway to influence neuroinflammation and pain signaling. ETX-155 is an neuroactive steroid that acts as a GABA ....

Andrew Levin , Bob Azelby , Valerie Morisset , Convergence Pharmaceuticals , Capital Group , Eliem Photo , Eliem Therapeutics , Juno Therapeutics , Alder Biopharmaceuticals , Seattle Based Juno , Intermediate Capital Group , Access Biotechnology , Samlyn Capital , Acorn Bioventures , ஆண்ட்ரூ லெவின் , வலேரி மோரிசெட் , குவிதல் மருந்துகள் , மூலதனம் குழு , ஜூனோ சிகிச்சை , ஆல்டர் உயிர் மருந்துகள் , சீட்டில் அடிப்படையிலானது ஜூனோ , இடைநிலை மூலதனம் குழு , நுழைவு உயிரி தொழில்நுட்பவியல் ,

Sana Biotechnology's IPO: List of early investors and executives who own stock

Sana Biotechnology went public before testing any treatments in people.
The cell and gene therapy startup won t launch clinical trials for at least a year.
Noted life sciences VCs Flagship Pioneering and Arch Venture Partners were its biggest shareholders pre-IPO.
Cell and gene editing startup Sana Biotechnology s shares jumped more than 40% on its first day of trading, making one of its investors stakes worth more than $1.5 billion.
The company sold 23.5 million shares at $25 apiece Thursday. Its stock price was up 40.40% at the end of the first day of trading, closing at $35.10 per share. Sana will have about 185 millions shares outstanding after the IPO, valuing the company at $6.5 billion. ....

United Kingdom , United States , Joshua Chao , Richard Mulligan , Steven Harr , Hans Bishop , Noubar Afeyan , Harvard Medical School , Canadian Pension Fund , Seattle Based Sana Biotechnology , Flagship Pioneering , Arch Venture Partners , Sana Biotechnology , Exchange Commission , Juno Therapeutics , Seattle Based Juno , F Prime Capital , Canadian Pension , Venture Partners , Canada Pension Plan , Prime Capital , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , ஜோஷுவா குழப்பம் , ரிச்சர்ட் முல்லிகன் , ஸ்டீவன் ஹார் ,